{"id":"placebo-for-mf","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3321989","moleculeType":"Small molecule","molecularWeight":"296.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action.","oneSentence":"This drug has no known mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:24.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07357727","phase":"PHASE3","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-15","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)","enrollment":460},{"nctId":"NCT04603495","phase":"PHASE3","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-09","conditions":"Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":430},{"nctId":"NCT04551066","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2021-05-24","conditions":"Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis","enrollment":252},{"nctId":"NCT04551053","phase":"PHASE3","title":"To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2021-05-26","conditions":"Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis","enrollment":177},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03705793","phase":"PHASE4","title":"Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-01-01","conditions":"Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis","enrollment":53},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT02953301","phase":"PHASE2","title":"Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)","status":"COMPLETED","sponsor":"4SC AG","startDate":"2016-11","conditions":"Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous","enrollment":201},{"nctId":"NCT01502371","phase":"PHASE2","title":"A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-01-25","conditions":"Asthma","enrollment":583},{"nctId":"NCT01135134","phase":"PHASE3","title":"Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-06","conditions":"Rhinitis, Allergic, Perennial","enrollment":333},{"nctId":"NCT00521599","phase":"PHASE4","title":"A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Asthma","enrollment":672},{"nctId":"NCT00383721","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1196},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00383240","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":781},{"nctId":"NCT00383435","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1055},{"nctId":"NCT00383552","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":746},{"nctId":"NCT00635882","phase":"PHASE2","title":"Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02","conditions":"Asthma, Airway Inflammation","enrollment":93},{"nctId":"NCT02767778","phase":"NA","title":"Low-frequency Pulsed Electromagnetic Fields (ELF-MF) as Treatment for Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Campus Bio-Medico University","startDate":"2016-04","conditions":"Stroke, Acute, Ischemic Stroke","enrollment":124},{"nctId":"NCT02811783","phase":"PHASE3","title":"Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL","status":"TERMINATED","sponsor":"Elorac, Inc.","startDate":"2017-01","conditions":"Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome","enrollment":59},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT02448381","phase":"PHASE3","title":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","status":"COMPLETED","sponsor":"Soligenix","startDate":"2015-12","conditions":"Cutaneous T-Cell Lymphoma","enrollment":169},{"nctId":"NCT01026870","phase":"PHASE3","title":"Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2012-06","conditions":"Asthma","enrollment":""},{"nctId":"NCT03855189","phase":"PHASE3","title":"Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1993-08-23","conditions":"Seasonal Allergic Rhinitis","enrollment":345},{"nctId":"NCT00783224","phase":"PHASE3","title":"A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Perennial Allergic Rhinitis","enrollment":351},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT03401229","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-15","conditions":"Nasal Polyposis","enrollment":413},{"nctId":"NCT03085797","phase":"PHASE3","title":"Effect of Mepolizumab in Severe Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-25","conditions":"Nasal Polyps","enrollment":414},{"nctId":"NCT03048773","phase":"NA","title":"Extracorporeal Shockwave Therapy for Knee Osteoarthritis","status":"COMPLETED","sponsor":"Taoyuan General Hospital","startDate":"2017-03-02","conditions":"Shockwave Therapy, Knee Osteoarthritis","enrollment":40},{"nctId":"NCT03525444","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-06-15","conditions":"Cystic Fibrosis","enrollment":405},{"nctId":"NCT03447249","phase":"PHASE3","title":"A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-07","conditions":"Cystic Fibrosis","enrollment":385},{"nctId":"NCT02593760","phase":"PHASE1","title":"A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-01-25","conditions":"Myelofibrosis","enrollment":10},{"nctId":"NCT03204058","phase":"PHASE2, PHASE3","title":"Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","startDate":"2016-02-10","conditions":"Chronic Periodontitis","enrollment":90},{"nctId":"NCT03204071","phase":"PHASE2, PHASE3","title":"Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","startDate":"2016-02","conditions":"Chronic Periodontitis","enrollment":90},{"nctId":"NCT00355810","phase":"NA","title":"Probiotics for Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2006-01","conditions":"Functional Gastrointestinal Disorders, Irritable Bowel Syndrome","enrollment":19},{"nctId":"NCT02250144","phase":"NA","title":"Foot Orthoses in Patellofemoral Pain Syndrome: a Prospective Randomized Study of Morpho-specific Versus Placebo Orthoses","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2015-06","conditions":"Patellofemoral Pain Syndrome","enrollment":80},{"nctId":"NCT02461667","phase":"PHASE2, PHASE3","title":"Alendronate Compared to Metformin in Chronic Periodontitis","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","startDate":"2014-07","conditions":"Chronic Periodontitis","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":300,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for MF","genericName":"Placebo for MF","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}